Alexza Pharmaceuticals, Inc. Reports 2015 Second Quarter Financial Results

MOUNTAIN VIEW, Calif., Aug. 6, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2015.  The net loss for the second quarter was $12.5 million compared to $6.0 million during the same quarter in 2014.  The net loss for the six months ended June 30, 2015 and 2014 was $12.9 million and $16.7 million, respectively.  At June 30, 2015, Alexza had consolidated cash, cash equivalents, and marketable securities of $15.7 million.

"We continue to see the incremental growth in the ADASUVE global launch.  ADASUVE is now available in 18 countries and we see continued increases in the number of hospitals stocking and using the product," said Thomas B. King, President and CEO of Alexza Pharmaceuticals.  "Importantly, we believe the sales during the ADASUVE launch do not reflect the clinical benefits ADASUVE can convey to patients, and we remain confident in ADASUVE's long-term commercial prospects.  Feedback from physicians and patients corroborate the positive clinical profile we observed with ADASUVE during its clinical development."

King continued, "Earlier this year we embarked on a plan to change our commercial production strategy to reduce our cash burn rate.

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.

Back to news